Incorporation of the IdyllaTM EGFR Mutation Test into NSCLC clinical work flows thus may help mitigate clinician and patient delay-related motivations to initiate potentially suboptimal treatments while awaiting molecular testing results regarding EGFR variants [28, 31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.